Clinical Trial

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Protocol Amendment History 5 changes
notable Trial sites expanded: 55 -> 63 locations 2026-08-13
notable Trial sites expanded: 45 -> 55 locations 2026-07-25
notable Trial sites expanded: 36 -> 45 locations 2026-06-05
notable Trial sites expanded: 26 -> 36 locations 2026-05-16
notable Trial sites expanded: 17 -> 26 locations 2026-05-01
Trial Details
NCT Number NCT07144163
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Enrollment 150 participants
Start Date 2025-12-11
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12